Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma.
High-dose chemotherapy and AHCT is the therapy of choice for patients with chemosensitive relapsed DLCL, but the part it plays in primary therapy in high-risk NHL patients and in primary and salvage therapy for non-DLCL subtypes remains to be clarified. The continuation of phase III trials is the most efficient and effective route to defining this role. A large number of NHL patients succumb to their disease, so it is hoped that alternate therapies, such as cytokines, monoclonal antibodies, and vaccines, may improve the results of HDT.
Johnston
L J
LJ
Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA. laura.johnston@stanford.edu
Horning
S J
SJ
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents